Biosign appoints new Chief Financial Officer and schedules Investor Conference
/NOT FOR DISTRIBUTION IN THE UNITED STATES OR THROUGH UNITED STATES WIRE
TORONTO, Jan. 6, 2014 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign"
or the "Company") is pleased to announce the appointment of Mr. Mario
Laflamme, CA, CPA as Chief Financial Officer, to replace Mr. William Randolph
(Randy) Polley, CA who will remain with the Company as a senior business
Mr. Laflamme will oversee Biosign's finance and accounting functions,
utilizing extensive financial management and corporate development experience
gained through working with rapidly growing firms in the technology sector in
both the United States and Canada. He most recently served as CFO for LED
Roadway Lighting, a Halifax, Nova Scotia based outdoor lighting technology
company; as Managing Director of Mass Tech Partners, a Massachusetts based
business and financial management firm; and as President & CFO of Univisions
Crimson Group, a corporate Audio/Video services firm formed by the merger of
Univisions and Crimson Tech, and sold to York Telecom. Notably, Mr. Laflamme
was Vice President, Finance and Vice President, Operations for The Learning
Company, (formerly SoftKey Software), a Canadian company that grew through
acquisitions to over $800 million in revenue and was later acquired by Mattel
The Company wishes to thank Mr. Polley for his service as CFO. He has helped
guide Biosign through our intense restructuring period, and his dedication,
skill and professionalism are greatly appreciated. We are pleased that he has
agreed to continue working with us as a key executive in the areas of business
development and sales.
Biosign's CEO Mr. Robert Kaul stated, "We are very pleased to welcome Mr.
Laflamme to Biosign as our new CFO. He brings us specific experience working
with fast growing companies in both Canada and the United States, which we
will need as we move forward with our previously articulated plan to grow by
acquisition in 2014 and beyond. Furthermore, as Biosign increasingly commits
to doing business in Atlantic Canada, Mr. Laflamme's location in Halifax will
be a benefit as we engage more deeply with government and industry
stakeholders in that region."
INVESTOR CONFERENCE CALL JANUARY 9, 2014
Biosign is pleased to announce an Investor Conference Call, scheduled for
Thursday, January 9(th), 2014 at 11:00 AM Eastern Daylight Time. During this
call, Biosign CEO Robert Kaul will read a prepared statement commenting on
recent news releases and providing additional discussion on the Company's
To participate in the call, please use the following login credentials:
Dial-In Number: Local: (718) 514-2085, Toll Free: 1-877-394-5901
No PIN number is required. Participants can dial Star 1 (*1) to ask a question
during the call - a live operator will be moderating.
In particular, Mr. Kaul will comment on the following announcements:
- "Biosign licenses award-winning applepeak source code" November 18, 2013
- "Biosign repatriates exclusive rights for Middle East and Asia" November 25,
- "Biosign and RJL Systems announce co-marketing agreement" December 23, 2013
- "Biosign invests in HR infrastructure company" December 24, 2013
- "Biosign announces $6.0 million software and services sale" December 27, 2013
- "Biosign acquires IBL Internet Business Logic Inc" December 31, 2013
Plus any additional releases issued prior to the date of the conference call.
Following the presentation, Mr. Kaul will answer a number of questions
submitted from participants regarding the business of the Company. The
conference call is open to any investor or stakeholder, including
shareholders, broker-dealers and other securities professionals. The call will
be recorded and available for review at http://biosign.com/investors.
To submit one or more questions to the CEO, please email your question to
firstname.lastname@example.org with the words "Investor Question for Conference Call" in the
subject line. Biosign management will endeavour to address as many questions
as possible in the one-hour time period allocated to the call.
Biosign CEO Robert Kaul stated, "Biosign has recently made a number of
material announcements related to our business plan. Management is pleased to
be able to communicate with investors and other interested parties in order to
place these announcements into greater context, and to address various
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled
health information solutions including the Pulsewave(®) Health Monitor and
the Healthanywhere™ Patient monitoring / self-management platform. The
Company's Pulsewave(®) Health Monitor solution enables pulse wave data
collection for cardiovascular clinical decision support and self-care, while
its Healthanywhere™ solution offers industry-leading remote patient
monitoring and patient centred care management. The Company also offers a
number of cardiovascular screening programs for consumers under its Heart
Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™
Dentist, and Heart Friendly™ Fitness. For more information on Biosign,
please visit www.biosign.com
This release contains forward-looking statements. Forward-looking statements,
without limitation, may contain the words believes, expects, anticipates,
estimates, intends, plans, or similar expressions. Forward-looking statements
are not guarantees of future performance. They involve risks, uncertainties
and assumptions and Biosign's actual results could differ materially from
those anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that could cause
actual events or results to differ materially from those projected in the
forward-looking statements. In the context of any forward-looking information
please refer to risk factors detailed in, as well as other information
contained in the company's filings with Canadian securities regulators
Neither TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
Biosign Contact Information:
Robert Kaul Chief Executive Officer Biosign Technologies Phone: (416) 218-9800
ext. 201 Email:email@example.com
To view this news release in HTML formatting, please use the following URL:
CO: Biosign Technologies Inc.
NI: HEA CONF 2575 WNEWS ERN
-0- Jan/06/2014 21:01 GMT
Press spacebar to pause and continue. Press esc to stop.